XNAS
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-23 | FY 2025 | -4.91 | -5.45 | -11.00% | $5.2M | ❌ Miss | +2.24% | -12.06% | +0.49% |
| 2025-03-24 | FY 2024 | — | -2.99 | — | $13.3M | — | -0.41% | -15.20% | -8.21% |
| 2024-09-09 |
| H1 2024 |
| — |
| -1.41 |
| — |
| $7.4M |
| — |
| -2.00% |
| -4.33% |
| -22.83% |
| 2024-04-02 | FY 2023 | -2.38 | -3.71 | -55.92% | $5.0M | ❌ Miss | +6.41% | +6.02% | +6.27% |
Showing last 4 quarters.